MedTrace Logo

Radiotherapy for Oligometastatic Prostate Cancer

NCT01859221 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2022-09-14

No results posted yet for this study

Summary

The purpose of this phase II study is to evaluate the outcomes of patients treated with an investigational radiation regimen using stereotactic radiotherapy for oligometastatic prostate cancer and to establish efficacy (producing a desired result or effect) and safety in this setting.

Conditions

Interventions

RADIATION

Stereotactic radiation

Stereotactic radiation

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Roi Dagan, MD, MS · University of Florida

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2022-09-13
Completion
2022-09-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01859221 on ClinicalTrials.gov